NCT06328608 - A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

April 30, 2031

Conditions

Fabry Disease

Interventions

DRUG

PRX-102 1 mg/kg every two weeks

Drug: PRX-102 1 mg/kg every two weeks

Trial Locations (11)

RECRUITING

Haukeland Universitetssjukehus, Bergen

RECRUITING

Emory Genetics Clinical Trials Center, Atlanta

RECRUITING

Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

NOT_YET_RECRUITING

University of Iowa, Iowa City

RECRUITING

University of Utah, Salt Lake City

NOT_YET_RECRUITING

Phoenix Children's, Phoenix

NOT_YET_RECRUITING

UK für Kinder- und Jugendheilkunde der PMU Salzburg, Salzburg

RECRUITING

Hopital Arnaud de Villeneuve, Montpellier

RECRUITING

Hospital Clinico Universitario De Santiago De Compostela, Santiago de Compostela

NOT_YET_RECRUITING

Great Ormond Street Hospital for Children NHS Foundation Trust, London